Advertisement

Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial

      Abstract

      Background

      Proton-pump inhibitors (PPIs) have been demonstrated to reduce rates of gastrointestinal events in patients requiring dual antiplatelet therapy (DAPT). Data are limited regarding the efficacy and safety of PPIs in high-risk cardiovascular subsets after acute coronary syndrome or percutaneous coronary intervention.

      Methods

      All patients enrolled in COGENT (Clopidogrel and the Optimization of Gastrointestinal Events Trial) were initiated on DAPT (with aspirin and clopidogrel) for various indications within the prior 21 days. These post hoc analyses of the COGENT trial evaluated the efficacy and safety of omeprazole compared with placebo in subsets of patients requiring DAPT for the 2 most frequent indications: 1) patients undergoing percutaneous coronary intervention (for any indication) within 14 days of randomization (n = 2676; 71.2%); and 2) patients presenting with acute coronary syndrome managed with or without percutaneous coronary intervention (n = 1573; 41.8%). Unadjusted Cox proportional hazards models were used to estimate effect sizes through final follow-up.

      Results

      Median follow-up duration was 110 days (interquartile range 55-167). In percutaneous coronary intervention-treated patients, omeprazole significantly reduced rates of composite gastrointestinal events at 180 days (1.2% vs 2.7%; hazard ratio [HR] 0.43; 95% confidence interval [CI], 0.22-0.85; P = .02) without increasing composite cardiovascular events (5.4% vs 6.3%; HR 1.00; 95% CI, 0.67-1.50; P = 1.00). Similarly, omeprazole lowered risk of the primary gastrointestinal endpoint at 180 days in patients presenting with acute coronary syndrome (1.1% vs 2.7%; HR 0.37; 95% CI, 0.13-1.01; P = .05) without a significant excess in cardiovascular events (5.6% vs 4.5%; HR 1.40; 95% CI, 0.77-2.53; P = .27).

      Conclusions

      PPI therapy attenuates gastrointestinal bleeding risk without significant excess in major cardiovascular events in high-risk cardiovascular subsets, regardless of indication for DAPT. Future studies will be needed to clarify optimal gastroprotective strategies for higher-intensity and longer durations of DAPT.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Eikelboom J.W.
        • Mehta S.R.
        • Anand S.S.
        • Xie C.
        • Fox K.A.
        • Yusuf S.
        Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.
        Circulation. 2006; 114: 774-782
        • Bhatt D.L.
        • Cryer B.L.
        • Contant C.F.
        • et al.
        Clopidogrel with or without omeprazole in coronary artery disease.
        N Engl J Med. 2010; 363: 1909-1917
        • Vardi M.
        • Cryer B.L.
        • Cohen M.
        • et al.
        The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.
        Aliment Pharmacol Ther. 2015; 42: 365-374
        • Southworth M.R.
        • Temple R.
        Interaction of clopidogrel and omeprazole.
        N Engl J Med. 2010; 363: 1977
        • Shah N.H.
        • LePendu P.
        • Bauer-Mehren A.
        • et al.
        Proton pump inhibitor usage and the risk of myocardial infarction in the general population.
        PLoS One. 2015; 10: e0124653
        • Sherwood M.W.
        • Melloni C.
        • Jones W.S.
        • Washam J.B.
        • Hasselblad V.
        • Dolor R.J.
        Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: A systematic review.
        J Am Heart Assoc. 2015; 4: e002245
        • Frelinger 3rd, A.L.
        • Lee R.D.
        • Mulford D.J.
        • et al.
        A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
        J Am Coll Cardiol. 2012; 59: 1304-1311
        • Frelinger 3rd, A.L.
        • Bhatt D.L.
        • Lee R.D.
        • et al.
        Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
        J Am Coll Cardiol. 2013; 61: 872-879
        • Banerjee S.
        • Weideman R.A.
        • Weideman M.W.
        • et al.
        Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.
        Am J Cardiol. 2011; 107: 871-878
        • Depta J.P.
        • Bhatt D.L.
        Omeprazole and clopidogrel: should clinicians be worried?.
        Cleve Clin J Med. 2010; 77: 113-116
        • Olsen A.S.
        • Lindhardsen J.
        • Gislason G.H.
        • et al.
        Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study.
        BMJ. 2015; 351: h5096
        • Vaduganathan M.
        • Bhatt D.L.
        Revisiting the clopidogrel-proton pump inhibitor interaction: from bench to bedside.
        Circ Cardiovasc Interv. 2015; 8https://doi.org/10.1161/CIRCINTERVENTIONS.115.003208
        • de Jong H.J.
        • Korevaar J.C.
        • van Dijk L.
        • Voogd E.
        • van Dijk C.E.
        • van Oijen M.G.
        Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care.
        BMJ Open. 2013; 3https://doi.org/10.1136/bmjopen-2013-003044
        • Vaduganathan M.
        • Bhatt D.L.
        • Cryer B.L.
        • et al.
        Proton-pump inhibitors reduce risk of gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy: Insights from the COGENT trial.
        J Am Coll Cardiol. 2016; 67: 1661-1671
        • Bhatt D.L.
        • Scheiman J.
        • Abraham N.S.
        • et al.
        ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.
        Circulation. 2008; 118: 1894-1909
        • Abraham N.S.
        • Hlatky M.A.
        • Antman E.M.
        • et al.
        ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
        Circulation. 2010; 122: 2619-2633
        • Moukarbel G.V.
        • Bhatt D.L.
        Antiplatelet therapy and proton pump inhibition: clinician update.
        Circulation. 2012; 125: 375-380